ROIV

Roivant Sciences Ltd. [ROIV] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ROIV Stock Summary

In the News

ROIV Financial details

Company Rating
-
Market Cap
8.82B
Income
4.32B
Revenue
123.24M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
904
Optionable
No
Shortable
Yes
Earnings
26 Jun 2024
P/E
-7.56
Forward P/E
-
PEG
0.16
P/S
88.46
P/B
9.22
P/C
-
P/FCF
-10.72
Quick Ratio
5.51
Current Ratio
5.84
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
5.35
EPS next Y
-
EPS next Q
-
EPS this Y
25.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-18.6%
Revenue last 5Y
92.41%
Revenue Q/Q
0.11%
EPS Q/Q
-1692.5%
-
-
-
-
SMA20
1.36%
SMA50
36.54%
SMA100
81.81%
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
-95%
ROC
-0.29%
Gross Margin
85%
Oper. Margin
-499%
Profit Margin
-1121%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.01-13.24
52W High
+69.96%
52W Low
+215.64%
RSI
68.05
Rel Volume
1.56
Avg Volume
7.44M
Volume
11.61M
Perf Week
6.74%
Perf Month
12.84%
Perf Quarter
91.46%
Perf Half Y
95.88%
-
-
-
-
Beta
1.342
-
-
Volatility
0.57%, 0.5%
Prev Close
3.54%
Price
22.095
Change
9.11%

Something similar

Top by Market Cap
1YD.DE
GOOG
M&M.NS
VFINX
ABEA.DE
Same Sector
FMTX
600329.SS
0JW9.L
IDXX
NKTR
Same Price Range
DX2Z.DE
ARRD.DE
VIMIAN.ST
KNT.TO
002155.SZ
Similar Market Cap
300212.SZ
NOV
DFAT
600370.SS
603043.SS

Company Profile

Healthcare Biotechnology
  • Volume Average 7.44M
  • Market Capitalization 8.82B
  • Employee 904
  • CEO Mr. Matthew Gline
  • Headquarters London,GB
  • IPO Date 2020-12-08
  • Website https://roivant.com

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.